Abbott's Profits Exceed Expectations, Tariff Costs Reach Hundreds of Millions

On April 16th local time, Abbott announced its financial results for the first quarter of 2025. The report shows that Abbott's net sales in the first quarter reached 10.36 billion US dollars, a year-on-year increase of 4%. Among them, the medical device segment has the highest proportion, with revenue of 4.895 billion US dollars, a year-on-year increase of 9.9%; the nutrition business revenue was 2.146 billion US dollars, a year-on-year increase of 3.8%; the generic drug business revenue was 1.26 billion US dollars, a year-on-year increase of 2.7%; the diagnostic business was affected by the decline in demand for COVID-19 testing, with a year-on-year decrease of 7.2%, but excluding this factor, the organic growth turned positive to +0.5%.